Drug Detail

Information about MPDL3280A

Generic Name
IND
MPDL3280A
Brand Name (US)
Manufacturer
Hoffman-La Roche
Drug Type
Immunotherapy
Delivery
Intravenous
Approval Status
Phase 3
Indications
Overall Strategy
Immune system
Strategy
Immunotherapy
Drug Category
PD-L1 inhibitor

The FDA has twice designated this drug as a breakthrough therapy.

An engineered anti PD-L1 antibody.

MPDL3280A (also known as anti-PDL1 and RG7446) is an investigational monoclonal antibody designed to interfere with a protein called PD-L1. MPDL3280A is designed to target PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, preventing it from binding to PD-1 and B7.1 on the surface of T cells. By inhibiting PD-L1, MPDL3280A may enable the activation of T cells, restoring their ability to effectively detect and attack tumor cells.